Bendamustine-Rituximab Induction Appears Effective in Mantle Cell Lymphoma
First-line bendamustine plus rituximab followed by ASCT and rituximab maintenance appears effective in mantle cell lymphoma.
First-line bendamustine plus rituximab followed by ASCT and rituximab maintenance appears effective in mantle cell lymphoma.
Researchers sought to determine the treatment and survival trends for patients with mantle cell lymphoma.
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed that acalabrutinib 100 mg tablets were bioequivalent to the acalabrutinib 100 mg capsules.
ASCT as first-line treatment for patients with MCL appears to be underutilized in the US community setting.
Adding ibrutinib to standard chemoimmunotherapy improved the median progression-free survival by 2.3 years.
Researchers determined a combination of ibrutinib with rituximab appears to be effective in elderly patients with MCL.
The best overall response rate was 98%, and the complete response rate was 89%.
Incyte has withdrawn the NDA for parsaclisib for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.
The study includes patients with relapsed/refractory and treatment-naïve mantle cell lymphoma.
Researchers are seeking to compare the efficacy and safety of the combination of ibrutinib and venetoclax compared with ibrutinib and placebo in patients with mantle cell lymphoma.